Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03754023




Registration number
NCT03754023
Ethics application status
Date submitted
12/11/2018
Date registered
27/11/2018
Date last updated
9/03/2021

Titles & IDs
Public title
Biomarker Rule in/Out in Patients With Acute Diseases for Validation of AKI (BRAVA) Acute Kidney Injury
Scientific title
The Potential Role of Biomarkers (Urine TIMP-IGFBP7) in Determining the Incidence of Acute Kidney Injury (AKI) in All-comers Patients Presenting to the Emergency Department With Acute Diseases
Secondary ID [1] 0 0
BRAVA Study
Universal Trial Number (UTN)
Trial acronym
BRAVA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Kidney Injury 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Injuries and Accidents 0 0 0 0
Other injuries and accidents
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Diagnosis / Prognosis - Urine-TIMP-IGFBP7 biomarker for AKI

Diagnosis / Prognosis: Urine-TIMP-IGFBP7 biomarker for AKI
Urine-TIMP-IGFBP7 biomarker for AKI
Intervention code [1] 0 0
Diagnosis / Prognosis
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Diagnostic performance of urine TIMP-IGFBP7 as early biomarker in ruling in or ruling out acute kidney damage in patients presenting to ED with acute diseases.
Timepoint [1] 0 0
48 hours
Secondary outcome [1] 0 0
Overall length in days of hospital stay
Timepoint [1] 0 0
30 hours
Secondary outcome [2] 0 0
Incidence of chronic kidney disease (CKD)
Timepoint [2] 0 0
30 days
Secondary outcome [3] 0 0
Overall mortality
Timepoint [3] 0 0
30 days
Secondary outcome [4] 0 0
Regional (different countries in Asia Pacific Region) incidence of AKI in a cohort of patients presenting to the ED with acute diseases
Timepoint [4] 0 0
48 hours

Eligibility
Key inclusion criteria
Patient Inclusion Criteria

- Age = 21 years

- >30% risk of developing AKI based on treating physicians' clinical evaluation AND/OR
Presence of ONE OF the following conditions:

- Suspected or confirmed sepsis.

- Acute decompensated heart failure.

- Prolonged gastrointestinal losses from vomiting or diarrhea

- Major trauma

- Major bleeding (e.g. gastrointestinal, pulmonary, genitourinary)

- Severe burns

- Diabetic crisis (DKA, HHS)

- Decompensated liver cirrhosis

- Acute coronary syndrome

- Emergent need for iodinated contrast studies

- Shock from any cause

Patient
Minimum age
21 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

- Age < 21 years.

- Unable to give informed consent

- Undergoing hemodialysis or peritoneal dialysis

- Pregnancy

- Terminal illness with < 6 months prognosis

- Do-not-resuscitate status

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/11/2019
Sample size
Target
Accrual to date
Final
818
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Prince of Wales Hospital - Sidney
Recruitment postcode(s) [1] 0 0
NSW2031 - Sidney
Recruitment outside Australia
Country [1] 0 0
India
State/province [1] 0 0
Hyderabad
Country [2] 0 0
Korea, Republic of
State/province [2] 0 0
Seoul
Country [3] 0 0
Singapore
State/province [3] 0 0
Singapore
Country [4] 0 0
Thailand
State/province [4] 0 0
Bangkok

Funding & Sponsors
Primary sponsor type
Other
Name
GREAT Network Italy
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The presence or development of AKI impacts on outcomes in patients presenting with acute
conditions to the ED. As a result, treating physicians are often concerned with the risk of
AKI and take such risk in consideration when making subsequent therapeutic and diagnostic
decisions which may result in delaying or withholding therapeutic measures in order to
prevent further kidney damage (i.e. avoid imaging studies with contrast media).

If clinicians could be informed early that a patient is at minimal risk for AKI, they could
deploy timely and optimal diagnostic and treatment procedures for the underlying disease of
the patient without major concerns for causing or exacerbating kidney damage
Trial website
https://clinicaltrials.gov/ct2/show/NCT03754023
Trial related presentations / publications
Ostermann M, Joannidis M. Acute kidney injury 2016: diagnosis and diagnostic workup. Crit Care. 2016 Sep 27;20(1):299. doi: 10.1186/s13054-016-1478-z.
Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honore PM, Joannes-Boyau O, Joannidis M, Korhonen AM, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015 Aug;41(8):1411-23. doi: 10.1007/s00134-015-3934-7. Epub 2015 Jul 11.
Wetz AJ, Richardt EM, Wand S, Kunze N, Schotola H, Quintel M, Brauer A, Moerer O. Quantification of urinary TIMP-2 and IGFBP-7: an adequate diagnostic test to predict acute kidney injury after cardiac surgery? Crit Care. 2015 Jan 6;19(1):3. doi: 10.1186/s13054-014-0717-4.
Public notes

Contacts
Principal investigator
Name 0 0
Salvatore Di Somma
Address 0 0
GREAT Network Italy
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03754023